Location History:
- Oxford, GB (2022)
- Abingdon, GB (2020 - 2024)
Company Filing History:
Years Active: 2020-2025
Title: Thomas Beauregard Schofield: Innovator in Respiratory Disease Treatment
Introduction
Thomas Beauregard Schofield is a notable inventor based in Abingdon, GB. He has made significant contributions to the field of medical science, particularly in the treatment of respiratory diseases. With a total of 8 patents, Schofield's work focuses on innovative compounds that modulate critical channels in the human body.
Latest Patents
Schofield's latest patents include groundbreaking compounds that serve as positive modulators of the calcium-activated chloride channel (CaCC), specifically TMEM16A. These compounds are designed to treat diseases and conditions that are influenced by the modulation of TMEM16A, with a particular emphasis on respiratory ailments. Another significant patent involves substituted benzodiazoliums that act as inhibitors of the epithelial sodium channel (ENaC). These compounds are useful for the treatment or prevention of respiratory diseases, skin conditions, and ocular conditions.
Career Highlights
Throughout his career, Schofield has worked with various companies, including Enterprise Therapeutics Limited and Tmem16a Limited. His innovative research and development efforts have positioned him as a key figure in the pharmaceutical industry, particularly in the realm of respiratory health.
Collaborations
Some of Schofield's notable coworkers include Duncan Alexander Hay and Jonathan David Hargrave. Their collaborative efforts have contributed to the advancement of research in respiratory disease treatments.
Conclusion
Thomas Beauregard Schofield's contributions to medical science through his patents and collaborations highlight his commitment to improving health outcomes for individuals with respiratory conditions. His innovative work continues to pave the way for future advancements in the field.